{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

HFpEF-INSIGHT 2.0: A Research Survey to understand the Awareness, Diagnosis, and Management of HFpEF Among HCPs and Insights on Evolving Treatments

Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. What percentage of heart failure cases in your clinical practice are HFpEF? *

  2. In your experience, what is the most common underlying factor contributing to HFpEF in your patients? *

  3. What are the key clinical signs or patient scenarios that prompt you to suspect HFpEF? *
  4. What do you perceive as the primary barrier to increasing awareness of HFpEF among healthcare professionals? *

  5. In your opinion, what improvements are needed in current diagnostic protocols for HFpEF? *
  6. Which of the following patient populations do you think require more active screening for HFpEF? (Multiple selections allowed) *

  7. Which criteria do you most frequently use to diagnose HFpEF in your practice? *

  8. What is your preferred diagnostic modality for confirming HFpEF? *

  9. What additional diagnostic tools or biomarkers do you think could improve the early identification of HFpEF? *
  10. How frequently do you encounter delayed HFpEF diagnosis being refered to you in your practice? *

  11. What is the most common challenge you face in accurately diagnosing HFpEF? *

  12. How important is managing comorbidities (e.g., obesity, hypertension, diabetes) in improving HFpEF outcomes? *
  13. Do you believe currently available diagnostic tools provide adequate sensitivity and specificity for HFpEF? Give Reasons *

  14. How would you compare the challenges of managing HFpEF versus HFrEF in clinical practice? *

  15. Which of the following do you consider to be the most significant unmet need in HFpEF management? *

  16. What do you consider to be the most significant gap in current HFpEF management guidelines? *
  17. What proportion of HFpEF patients in your practice experience recurrent hospitalizations despite optimal management? *

  18. How frequently do you incorporate multidisciplinary teams (e.g., cardiologists, nephrologists, diabetologists) in managing HFpEF patients? *

  19. What initiatives or resources do you think would help improve HFpEF awareness among healthcare providers? *
  20. Which class of therapy have you found most beneficial for managing HFpEF? *

  21. In your practice, how often do you initiate RAAS inhibitors (ACEi/ARB) in HFpEF patients with normal blood pressure? *
  22. How often do you prescribe SGLT2 inhibitors for HFpEF management? *

  23. What has been your experience with SGLT2 inhibitors in HFpEF management, and what role do you see for them long-term? *
  24. Do you foresee a significant role for newer therapies such as GLP-1 RA or non- steroidal MRA in HFpEF management? Give reasons *

  25. How do you think newer therapies such as GLP-1 RA or non-steroidal MRA could impact HFpEF management? *
  26. How do you primarily assess treatment efficacy in HFpEF patients? *

  27. In your practice, what percentage of HFpEF patients achieve good symptom control with current therapies? *

  28. What challenges do you face in optimizing treatment strategies for HFpEF patients? *
  29. Which comorbidity is most frequently associated with HFpEF in your practice? *

  30. How do you perceive the prognosis of HFpEF compared to HFrEF? *

  31. Which factor do you think has the most significant impact on HFpEF management outcomes? *

  32. Which of the following do you consider the most common reason for poor medication adherence in HFpEF patients? *

  33. How significant do you consider lifestyle modifications (e.g., diet, exercise) in the overall management of HFpEF? *
  34. If you could implement one major change in the healthcare system to improve HFpEF management, what would it be?
  35. Do you think newer therapies (e.g., GLP-1 RA, non-steroidal MRA) should be incorporated earlier in the HFpEF treatment algorithm? If Yes in which patient profile? *